We find that find that there are two main factors which influence the type of greenhouse system that a group may consider for cannabis production.

Different groups may have a different perspective as to how concerned they are regarding these particular variables. For example, producers for a medical market facing strict regulations regarding sanitation and purity generally have different priorities than a producer for a recreational market, or those producing exclusively for extracts. Based on these priorities, a greenhouse project may incorporate fundamentally different approaches to things like ventilation and climate management. The two main factors are:

KELOWNA, BC / ACCESSWIRE / January 20, 2016 / Lexaria Corp. (OTCQB:LXRP) (CSE:LXX) (the “Firm”) could be very happy to announce research knowledge from human topics demonstrating vital elevation of systemic nitric oxide ranges as a surrogate biomarker for cannabidiol (CBD) bioabsorption in response to ingestion of Lexaria’s merchandise.

As beforehand introduced, the research was undertaken to offer medical help for the CBD bioavailability enhancing properties of Lexaria’s patent-pending know-how, on the premise that bioavailable CBD is understood to raise ranges of the endocannabinoid anandamide within the human physique which, in flip, stimulates launch of nitric oxide within the vascular system.

Phillip Morris and Syqe, an Israeli medical device company with an inhaler type delivery system have announced a $20m investment.  The cigarette manufacturer will benefit  from a Medtech footprint to understand the potential to significantly reduce damage from smoking traditional nicotine products.

A study at Rambam Hospital where the cannabis inhaler was examined, reported it both safe and effective. In Israel there is an estimated 24, 000  medical cannabis patients.

As marijuana continues to move into the mainstream, dozens of Bay Area startups are banking on big business opportunities in the cannabis industry.

"We are at this precipice: There is a lot of money — real capital — that wants to come into the space," said Ben Larson, who runs Gateway Incubator, a cannabis startup incubator in downtown Oakland.

Medical cannabis dispensaries can’t read your brain to find out what pot strains you prefer, but one tech company might soon change that.

Emerging cannabis tech company PotBotics has found a way to use existing electroencephalogram (EEG) technology to make medical marijuana recommendations best suited for the specific medical conditions of users, the New York Daily News reports.

EEG technology employs the use of electrodes placed on areas of the scalp to detect any sort of abnormalities in brain activity.

Eaze delivers medical medical marijuana in plastic containers. The company has released the first compilation of data about its customers.

Many medical cannabis users indulge in the morning, “waking-and-baking,” and Northern Californians prefer trippier kinds of marijuana than folks in Southern California.

Those are among the insights gleaned from the aggregate use patterns of 100,000 clients of Eaze, a medical marijuana delivery service that released information Tuesday about users in the 80 California cities where it operates.

Marijuana Movement

Eaze CEO Keith McCarty hopes that sharing the data will help shape the new medical marijuana regulations being crafted in California.

It’s becoming an all too familiar occurrence, Instagram deleting accounts related to the cannabis industry. This week’s victim, Dixie Brands, manufacturer of premium cannabis-infused products.

“This is just one more example of the daily injustices and discriminations we face as an industry,” said Dixie Brands CEO, Tripp Keber.

According to Chief Marketing Officer, Joe Hodas, Instagram deleted the company’s account and gave no explanation or responses to their repeated inquiries.

Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex^® for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex^® for intractable epilepsy. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting Professor, Chinese Academy of Sciences.

There was a lot of discomfort surrounding one of the largest and most highly anticipated events at the Consumer Electronics Show (CES) last week, the Extreme Tech Challenge. The reason for this discomfort stemmed from a cannabis related technology company’s participation in the Extreme Tech Challenge.

Although many technology companies say they are the most progressive in the country; when it comes to cannabis, they are not. Such companies actually operate under the most regressive policies when it comes to cannabis.

Negative Bias is Nothing New for Cannabis Related Tech Companies

On Friday several French agencies opened an investigation into a clinical drug trial that has hospitalized six men in the last week, leaving one permanently brain dead and three in critical condition, likely with permanent brain damage.